RPP38: A Protein Targeted for Drug Development and Biomarker Analysis

Target Name: RPP38

NCBI ID: G10557

RPP38

RPP38: A Protein Targeted for Drug Development and Biomarker Analysis

Ribonuclease P (38kD) (RPP38) is a protein that is expressed in various cell types of the human body, including white blood cells, liver, and pancreas. It is a member of the nucleotide-binding oligomerase (NBO) family, which is involved in the regulation of DNA replication, repair, and other important cellular processes.

RPP38 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are important for human health. For example, RPP38 has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, RPP38 has also been shown to be a valuable biomarker for several diseases. For example, RPP38 has been used as a biomarker for several types of cancer, including breast, ovarian, and prostate cancer. In In addition, RPP38 has also been used as a biomarker for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

One of the key advantages of RPP38 as a drug target is its relatively simple structure. RPP38 is a single protein that consists of a nucleotide-binding oligomerase domain and a G protein-coupled receptor (GPCR) domain. The NBO domain is responsible for the protein's ability to bind to DNA, while the GPCR domain is responsible for transmitting signals from the protein to downstream signaling pathways.

The NBO domain of RPP38 is known for its ability to bind to specific DNA sequences, which allows it to play a role in the regulation of DNA replication and repair. In addition, the NBO domain of RPP38 has been shown to play a role in the regulation of cellular processes that are important for human health, including cell growth, apoptosis, and inflammation.

The GPCR domain of RPP38 is responsible for transmitting signals from the protein to downstream signaling pathways. This domain has been shown to play a role in the regulation of cellular processes that are important for human health, including cell signaling, neurotransmission, and inflammation.

In addition to its potential as a drug target, RPP38 has also been shown to be a valuable biomarker for several types of diseases. For example, RPP38 has been used as a biomarker for several types of cancer, including breast, ovarian, and prostate cancer . In addition, RPP38 has also been used as a biomarker for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.

One of the key advantages of RPP38 as a biomarker is its ability to be easily modified and characterized. This allows researchers to study the protein's function in different cellular contexts and to test its potential as a biomarker for various diseases.

In conclusion, RPP38 is a protein that has been shown to play a role in the regulation of various cellular processes that are important for human health. As a potential drug target, RPP38 is an attractive target for researchers to study its function and its potential as a therapeutic agent. In addition, as a biomarker, RPP38 has been shown to be a valuable tool for the diagnosis and treatment of various diseases. Further research is needed to fully understand the protein's role in these processes and to develop safe and effective therapies based on it.

Protein Name: Ribonuclease P/MRP Subunit P38

Functions: Component of ribonuclease P, a ribonucleoprotein complex that generates mature tRNA molecules by cleaving their 5'-ends (PubMed:9037013, PubMed:9630247, PubMed:10444065, PubMed:30454648). Also a component of the MRP ribonuclease complex, which cleaves pre-rRNA sequences (PubMed:28115465)

The "RPP38 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPP38 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets